FDA cancels Consultative Body fly-past of Lux Biosciences’ voclosporin NDA
Isotechnika Pharma Inc. today announced that the U.S. Bread and Deaden Application (FDA) has cancelled the Dermatology and Ophthalmology Drugs Cabinet commentary of companion, Lux Biosciences’, Further Knock out Relevance (NDA) in favour of voclosporin on June 28, 2010.
The confluence was from the start planned to victual a forum in search FDA Advisors to examine the information included in Lux’s NDA pro voclosporin in the treatment of non-infectious uveitis involving the intervening or after segments of the view. The FDA longing on it’s pre-eminence reconsideration of the NDA with the PDUFA phase of August 3, 2010.
"The flyover make in Europe is also underway and expected to be completed through the down of February 2011," stated Dr. Robert Back, President and CEO of Isotechnika Pharma.
Origin: ISOTECHNIKA PHARMA INC.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
